Any current/future new fundraising through debt or equity?

The company is open to raising capital but has not started any formal process yet (Page 13). Informal discussions are ongoing with associates and advisors regarding fundraising (Page 13). There is openness to bringing in equity players either in the medical devices subsidiary or in the parent company (Page 22). No specific timelines or amounts have been provided; plans will be announced once finalized (Page 13, 22). The company is also open to partnerships, M&A, and inviting new investors to the board to support growth (Page 22). Previously, inability to access the market limited fundraising,

Any current/future capex/capital investment/strategic investment?

Capex of around ₹22 Crores planned for the year, including ₹12 Crores spent and ₹5 Crores work in progress (Page 20). ₹45 Crores investment in medical devices over nine months, showing significant focus on this segment (Page 20). Expansion planned to increase capacity from 300 KL to 1000 KL over three years for API segment, requiring additional capex (Page 19). Setting up plant for ANDA and ABS, but filing is 2 years away due to validation process (Page 21). Demerger of medical devices business into a separate 100% owned subsidiary to attract better capital, customers, and talent (Page

Future growth expectations in sales/revenue/volumes?

The company has maintained a historical CAGR revenue growth of around 25%, currently achieving 30% growth, and is comfortable sustaining 20-30% CAGR going forward. Medical devices segment has grown at a CAGR of approximately 41-46% and is expected to continue strong growth with capacity expansions and wider market reach. Online sales have surged significantly, with a 441% increase quarter-on-quarter and 30-40% ongoing quarterly growth, indicating strong future momentum. Expansion in API production capacity planned from 300 KL to 1000 KL over 3 years to meet growing demand, enabling expon

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets a compounded annual growth rate (CAGR) of 25% to 30% in sales across businesses. Medical devices have exhibited higher growth rates (~41% CAGR) but such high growth may normalize due to small base effects. Continued investments in medical devices and online channels are expected to boost future topline and profitability. EBITDA margins may see short-term compression due to heavy investments in marketing and devices, but long-term margins are expected to improve as scale increases. OTC business currently margin-light due to investments but expected to improve with market tra

Current/ Expected Orderbook/ Pending Orders?

Morepen Laboratories is expecting approval for the Sputnik vaccine drug license. Once approved, they plan to sign an agreement with RDIF, with bulk supply expected from Serum. Production capacity for Sputnik vaccine is up to 5 million units per month (about 25 million dosages). Actual production quantity depends on bulk supply from RDIF or Serum; no fixed estimate currently. Demand is driven by Russia's high COVID case counts (150,000 daily) and need in third-world countries. WHO approval of Sputnik is anticipated to trigger orders. The situation is dynamic ("moving parts"), so Morepen is caut

Morepen Laboratories LtdQ3 FY22Pharmaceuticals & Biotechnology

Morepen Laboratories Ltd Q3 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹119P/E: 56.2Market Cap: ₹6.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company has maintained a historical CAGR revenue growth of around 25%, currently achieving 30% growth, and is comfortable sustaining 20-30% CAGR going forward.
Medical devices segment has grown at a CAGR of approximately 41-46% and is expected to continue strong growth with capacity expansions and wider market reach.
Online sales have surged significantly, with a 441% increase quarter-on-quarter and 30-40% ongoing quarterly growth, indicating strong future momentum.
Expansion in API production capacity planned from 300 KL to 1000 KL over 3 years to meet growing demand, enabling exponential sales growth through new molecule opportunities.
New product launches (e.g., US FDA-approved Fexofenadine, Dapagliflozin, fertility range) and increased marketing investments are expected to further drive topline growth.
The forthcoming authorization for Sputnik vaccine production could open a substantial new revenue stream, though dependent on bulk supply availability.
Strategic focus on global markets, particularly in neighboring countries and beyond, to capture larger market share.

Margin guidance

Category 3

The company targets a compounded annual growth rate (CAGR) of 25% to 30% in sales across businesses.
Medical devices have exhibited higher growth rates (~41% CAGR) but such high growth may normalize due to small base effects.
Continued investments in medical devices and online channels are expected to boost future topline and profitability.
EBITDA margins may see short-term compression due to heavy investments in marketing and devices, but long-term margins are expected to improve as scale increases.
OTC business currently margin-light due to investments but expected to improve with market traction.
R&D spend is increasing aiming to capture opportunities from 15 APIs going off-patent through 2030, targeting 10% global market share in key APIs.
Overall earnings/profits expected to improve as new capacities come online and investments mature.
Management confident of exponential sales growth with better capital access and expanded capacities.

See what Morepen Laboratories Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company is open to raising capital but has not started any formal process yet (Page 13).
Informal discussions are ongoing with associates and advisors regarding fundraising (Page 13).
There is openness to bringing in equity players either in the medical devices subsidiary or in the parent company (Page 22).
No specific timelines or amounts have been provided; plans will be announced once finalized (Page 13, 22).
The company is also open to partnerships, M&A, and inviting new investors to the board to support growth (Page 22).
Previously, inability to access the market limited fundraising, but the current situation is described as a "historical moment" allowing for capital infusion (Page 22).
No mention of new debt raising; focus appears to be more on equity capital raising.

Order book

Morepen Laboratories is expecting approval for the Sputnik vaccine drug license.
Once approved, they plan to sign an agreement with RDIF, with bulk supply expected from Serum.
Production capacity for Sputnik vaccine is up to 5 million units per month (about 25 million dosages).
Actual production quantity depends on bulk supply from RDIF or Serum; no fixed estimate currently.
Demand is driven by Russia's high COVID case counts (150,000 daily) and need in third-world countries.
WHO approval of Sputnik is anticipated to trigger orders.
The situation is dynamic ("moving parts"), so Morepen is cautiously optimistic but unable to provide firm orderbook numbers at present.

See what Morepen Laboratories Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Capex of around ₹22 Crores planned for the year, including ₹12 Crores spent and ₹5 Crores work in progress (Page 20).
₹45 Crores investment in medical devices over nine months, showing significant focus on this segment (Page 20).
Expansion planned to increase capacity from 300 KL to 1000 KL over three years for API segment, requiring additional capex (Page 19).
Setting up plant for ANDA and ABS, but filing is 2 years away due to validation process (Page 21).
Demerger of medical devices business into a separate 100% owned subsidiary to attract better capital, customers, and talent (Page 14).
Increased R&D spending (up 58%) primarily in API and finished dosages, with plans to ramp up further as topline grows (Page 12).
Heavy investments in meters and marketing for medical devices, including celebrity endorsements, to expand market reach (Pages 7, 11).
Open to bringing equity investors or partners via M&A to support growth, including in medical devices or parent company (Page 22).

Track Morepen Laboratories Ltd — get its next earnings analysis in your feed

How does Morepen Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisMorepen Laboratories Ltd

Rev 2Mar 3

See where Morepen Laboratories Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Morepen Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Morepen Laboratories Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Morepen Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
FDC Ltd (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →